Drugs & Therapy Perspectives

, Volume 29, Issue 5, pp 145–148 | Cite as

Base the pharmacological treatment of post-stroke muscle spasticity on the needs and preferences of the patient

Disease Management


The pharmacological treatment of post-stroke muscle spasticity should be individualized according to several factors, including treatment objectives and the patient’s preferences. Botulinum neurotoxin is the first-line treatment, with peripheral nerve blocks being an option for spasticity of the proximal lower limb muscles. The use of oral muscle relaxants should be limited, as they are associated with the risk of generalized weakness and systemic adverse effects.



This article was adapted from Drugs & Aging 2012;29(12):941–7 [1]. The preparation of these articles was not supported by any external funding


  1. 1.
    Bakheit AMO. The pharmacological management of post-stroke muscle spasticity. Drugs Aging. 2012;29(12):941–7.Google Scholar
  2. 2.
    Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16(5):515–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Lundström E, Smits A, Borg J, et al. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke. 2010;41(2):319–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Royal College of Physicians of London, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London: Royal College of Physicians; 2009.Google Scholar
  5. 5.
    Ward AB, Aquilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity: a European consensus statement. J Rehabil Med. 2003;35(2):98–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med. 2009;52(10):746–56.PubMedCrossRefGoogle Scholar
  7. 7.
    Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized double-blind placebo controlled trial. Neurology. 1996;46(5):1306–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Bakheit AMO, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke. Stroke. 2000;31(10):2402–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Bakheit AMO, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb muscle spasticity in patients with stroke. Eur J Neurol. 2001;8(6):559–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med. 2002;347(6):395–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Bakheit AMO, Ward CD, McLellan DL. Generalised botulismlike syndrome following intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62(2):198.PubMedCrossRefGoogle Scholar
  12. 12.
    Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol. 1995;2:17–8.Google Scholar
  14. 14.
    Odergren T, Hjaltasaon H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose of equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2005;133(6):836–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Hatheway CH, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 93–107.Google Scholar
  17. 17.
    Bakheit AMO, Liptrot A, Newton R, et al. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35(1):36–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil. 1996;10:41–4.Google Scholar
  19. 19.
    Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30(16):1230–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Mueller ME, Gruenthal M, Olsen WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78(5):521–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Gruenthal M, Mueller ME, Olsen WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35(10):686–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Cutter NC, Scott DD, Johnson JC. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled randomized trial. Arch Phys Med Rehabil. 2000;81(2):164–9.PubMedGoogle Scholar
  23. 23.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9295):1517–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Adis, 41 Centorian DriveAucklandNew Zealand

Personalised recommendations